Sionna Therapeutics, Inc. — Form SCHEDULE 13D/A
Filed September 21, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 15/100
What the filing says
RA Capital Management, L.P. filed an amended Schedule 13D/A regarding beneficial ownership in Sionna Therapeutics, Inc. (public market value ~$342M). The filing was submitted on 2026-09-21. The document does not provide specific details on share count, ownership percentage, dollar amounts, or what substantive changes were made in the amendment.
Why this rating
Amended 13D is routine regulatory disclosure. No material ownership changes, transactions, or strategic shifts are specified in the header data.
See more from September 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.